Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > comgrats
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Nov 26, 2023 12:35pm
266 Views
Post# 35753452

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:comgrats

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:comgratsIf you want to see how chronic advances ... you're going to have to wait for the news releases.  Just like me.

I would expect ATE to visit their local FDA office (hahaha) and discuss how acute/chronic move foward in the fastest possible manner.  There will be some negotiations required here - I'm sure - and we could get laughed out of the FDA.

I would also expect that we will do as much as physically possible during P2 Acute ... to prove parts of  chronic as well.  Again ... I'm guessing.  We have to wait for information but these are the questions I'd be asking of the FDA.

I would arm myself with old data, with new data (P1-acute), with DILIsym (acute) and DILIsym (chronic) and I would go to that office with the best case I can make for an OTENA-chronic plan.

Again - that's just me.

and ...

I'm fine with being wrong.

I am at peace with myself.       : )
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities